Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
What did FDA say about TB-500 in 2026
About this article Cite this article Pountos, I., Panteli, M., Lampropoulos, A
The safety data
BPC-157 promotes VEGFR2 receptor internalization, triggering phosphorylation of Akt at specific sites (Ser473 and Thr308)
Comparison with Standard Treatments Studies comparing BPC-157 to becaplermin (the active ingredient in Regranex, an FDA-approved treatment for diabetic foot ulcers) found BPC-157 produced superior results in several parameters
Furthermore, there arent any plausible pharmacological mechanisms to support such effects
US$ 25.62
US$ 26.52
US$ 21.80
US$ 23.12
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 27.77
US$ 27.04
US$ 28.38
